This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia

September 8th, 2014

Chronic obstructive pulmonary disease (COPD) is associated with eosinophilic airway inflammation in 10–20% of patients.

Benralizumab, a monoclonal antibody, has been shown to decrease the number of blood and sputum eosinophils. In this trial of 101 patients with COPD whether benralizumab reduces the number of acute exacerbations was investigated.

Benralizumab was found to be no more effective at preventing acute COPD exacerbations than placebo overall.

However, the authors conclude that subgroup analyses suggest more research into the use of benralizumab in patients with COPD and eosinophilia is required.

More information:
www.thelancet.com/journals/lan … (14)70187-0/abstract

Provided by Lancet

Citation: Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia (2014, September 8) retrieved 28 March 2024 from https://sciencex.com/wire-news/171600390/benralizumab-for-chronic-obstructive-pulmonary-disease-and-sputu.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.